Placental peptides as markers of gestational disease

Page, NM; Kemp, CF; Butlin, David; Lowry, P. J.

doi:10.1530/rep.0.1230487

Cited by 59 publications

(35 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By analogy with other amniotic fluid and serum screening tests (eg, a␣-fetoprotein for neural tube defects), we predicted that peptides identified within infected amniotic fluid could also be detected in maternal serum and might lead to the development of noninvasive diagnostic tests. 35 Our preliminary results using pooled maternal serum samples suggest the feasibility of this approach, in that IGFBP-1-restrictive fragment and calgranulin B are 2 such candidate biomarkers that appear in both amniotic fluid and maternal blood during IAI but not in the absence of infection ( Figure 3B). In contrast, elevated IL-6 concentrations have not been reported in maternal serum in association with intra-amniotic infection.…”

Section: Commentmentioning

confidence: 79%

Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers

Gravett¹

2004

JAMA

274

202

View full text Add to dashboard Cite

ESPITE IMPROVEMENTS IN PRE-natal care, preterm birth occurs in 11.8% of births in the United States and remains the major obstetrical problem in developed countries. 1 Recently, intraamniotic infection (IAI) has been implicated as a major cause of preterm birth. Intra-amniotic infections cause more than 50% of very low-birthweight neonates born before 30 weeks of gestation and account for the highest number of neonatal deaths, the most serious complications, and a disproportionate share of aggregate perinatal health care costs (estimated in the United States to be $4 billion to $6 billion annually). 2,3 Current evidence indicates that if a microorganism causes preterm birth, it usually does so by infection of the chorioamnion and the amniotic fluid or fetus. Infection of the amniotic fluid or the fe-Author Affiliations are listed at the end of this article.

show abstract

Section: Commentmentioning

confidence: 79%

Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers

Gravett¹

2004

JAMA

274

202

View full text Add to dashboard Cite

show abstract

“…DNA sequence variations and polymorphisms caused by exogenous or endogenous factors can cause functional differences at the protein level, limiting the ability of genetic tests to predict the risk of multifactorial disorders of pregnancy such as pre-eclampsia and preterm labour (Shimizu & Bryant-Greenwood 2004). Several proteins have been observed to have significant associations with these pathologies (Cooper et al 1993, Masse et al 2002, Page et al 2002, Goldenberg et al 2003. However, thus far they have not demonstrated the sensitivity, specificity or predictive values required for accurate detection of women at risk for these disorders.…”

Section: Clinical Proteomics and Pregnancy Disordersmentioning

confidence: 99%

An emerging role for comprehensive proteome analysis in human pregnancy research

Shankar¹,

Gude²,

Cullinane³

et al. 2005

Reproduction

View full text Add to dashboard Cite

Elucidation of underlying cellular and molecular mechanisms is pivotal to the comprehension of biological systems. The successful progression of processes such as pregnancy and parturition depends on the complex interactions between numerous biological molecules especially within the uterine microenvironment. The tissue-and stage-specific expression of these biomolecules is intricately linked to and modulated by several endogenous and exogenous factors. Malfunctions may manifest as pregnancy disorders such as preterm labour, pre-eclampsia and fetal growth restriction that are major contributors to maternal and perinatal morbidity and mortality. Despite the immense amount of information available, our understanding of several aspects of these physiological processes remains incomplete. This translates into significant difficulties in the timely diagnosis and effective treatment of pregnancy-related complications. However, the emergence of powerful mass spectrometry-based proteomic techniques capable of identifying and characterizing multiple proteins simultaneously has added a new dimension to the field of biomedical research. Application of these high throughput methodologies with more conventional techniques in pregnancy-related research has begun to provide a novel perspective on the biochemical blueprint of pregnancy and its related disorders. Further, by enabling the identification of proteins specific to a disease process, proteomics is likely to contribute, not only to the comprehension of the underlying pathophysiologies, but also to the clinical diagnosis of multifactorial pregnancy disorders. Although the application of this technology to pregnancy research is in its infancy, characterization of the cellular proteome, unearthing of functional networks and the identification of disease biomarkers can be expected to significantly improve maternal healthcare in the future.

show abstract

“…Identification of proteins specific to reproduction and pregnancy is likely to contribute to the comprehension of the underlying pathophysiology and to the discovery of relevant biomarkers (Brewis, 1999;Page et al, 2002;Jauniaux et al, 2003). If detected in early pregnancy, or before the development of clinical symptoms, they can be used as suitable disease markers, whereas those detected at later stages are likely to be more specific and may be closely related to the phenotype of the disease.…”

Section: Introductionmentioning

confidence: 99%

Mass spectrometry‐based proteomics in reproductive medicine

Kοlialexi¹,

Mavrou²,

Spyrou

et al. 2008

Mass Spectrometry Reviews

View full text Add to dashboard Cite

The emergence of powerful mass spectrometry-based proteomic techniques has added a new dimension to the field of biomedical research. Application of these high throughput methodologies in pregnancy-related pathology has contributed to the comprehension of the underlying pathophysiologies and the successful identification of relevant protein biomarkers that can potentially change early diagnosis and treatment of several medical conditions related to human pregnancy. Most of the existing research on human reproduction and gestation has focused on follicular fluid, cervical/vaginal fluid, and amniotic fluid. Although proteome technologies in reproductive medicine research are not as yet widely applied, characterization of the proteome of reproductive fluids can be expected to significantly improve maternal healthcare. This article aims to summarize the applications of mass spectrometry based technology on the most important and specific biological fluids related to reproduction and gestation.

show abstract

Placental peptides as markers of gestational disease

Abstract: Di Iorio R, Marinoni E, Anceschi MM, Emiliani S, Letizia C and Cosmi EV (1996)

Cited by 59 publications

References 8 publications

Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers

Diagnosis of Intra-amniotic Infection by Proteomic Profiling and Identification of Novel Biomarkers

An emerging role for comprehensive proteome analysis in human pregnancy research

Mass spectrometry‐based proteomics in reproductive medicine

Contact Info

Product

Resources

About